Comparison on long-term effects of atorvastatin or pravastatin combined with clopidogrel for patients undergoing coronary stenting: A randomized controlled trial

National Medical Journal of China

Volumn 89, Issue 32, 2009, Pages 2240-2244

  Han, Ya Ling ^a   Zhang, Zi Long ^a   Li, Yi ^a   Wang, Shou Li ^a   Jing, Quan Min ^a   Wang, Zu Lu ^a   Wang, Dong Mei ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

Angioplasty, transluminal, percutaneous coronary; Atorvastatin; Clopidogrel; Provastatin

Indexed keywords

ATORVASTATIN; CLOPIDOGREL; DRUG DERIVATIVE; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PRAVASTATIN; PYRROLE DERIVATIVE; TICLOPIDINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICHOLESTEREMIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; PRAVASTATIN; PYRROLES; TICLOPIDINE; TIME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84871306661     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2009.32.004     Document Type: Article

References (12)

1. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation, 2003, 107: 32-37.
2. Ray KK, Cannon CP, Ganz P. Beyond lipid lowering: what have we learned about the benefits of statins from the acute coronary syndromes trials? Am J Cardiol, 2006, 98: 18P-25P.
3. Neubauer H, Gunesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function a flow cytometry study. Eur Heart J, 2003, 24: 1744-1749.
4. Vinholt P, Poulsen TS, Korsholm L, et al. The antiplatelet effect of clopidogrel is not atenuated by statin treatment in stable patients with ischemic heart disease. Thromb Haemost, 2005, 94: 438-443.
5. Angiolillo D, Fernandez-Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome P4503A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vase Biol, 2006, 26: 1895-1900.
6. Fontana P, Dupont A, Gandrille S, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation, 2003, 108: 989-995.
7. 2007, 35: 788-792.
8. Mukherjee D, Kline Rogers E, Fang J, et al. Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome. Heart, 2005, 91: 23-26.
9. Jacqueline S, Danielle M, Steven R, et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol, 2007, 50: 291-295.
10. Amir L, Marc J, Gregory R, et al. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients a pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22(PROVE IT-TIMI 22) analysis. Am Heart J, 2008, 155: 954-958.
11. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3 A and is inhibited by atorvastatin. Drug Metab Dispos, 2003, 31: 53-59.
12. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost, 2000, 84: 891-896.